Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

RSS icon
Bruce Wilkoff, MD, a veteran cardiologist with Cleveland Clinic

Cardiologist Bruce Wilkoff remembered as a ‘pioneer’ of electrophysiology, ‘beacon of medical excellence’

Friends, colleagues and professional societies have all shared loving tributes to the veteran electrophysiologist, who died at the age of 69. 

Stephanie Golab, MD, NYU Grossman School of Medicine, explains statistics on heart transplant outcomes in older adults

It may be time to revisit patient selection protocols for heart transplants

In a new video interview, Stephanie Golab, MD, examines the latest data on heart transplant outcomes in older adults.

AI artificial intelligence stethoscope doctor

AI models for predicting heart failure still far from perfect

Advanced AI models can evaluate a patient's heart failure risk using 12-lead ECG data—but there is still some room for improvement. 

Thumbnail

Falls, infections much more likely among Medicare patients treated at private equity-owned hospitals

Private equity is becoming more and more influential in many healthcare specialties, including cardiology. This has prompted increased speculation about the impact such investments may have on patient outcomes.

Transplant recipients may face risk of aging-related complications if receiving a much older heart

Early research suggests initiating therapy with senescence-inhibiting drugs could limit the risk of these side effects. 

HeartMate 3 LVAD abbott

Former FDA employees share concerns about heart device safety data

Abbott's HeartMate 3 LVAD is the only FDA-approved device of its kind currently available in the United States. Should reports of adverse events worry cardiologists? Or are they to be expected when treating such a vulnerable patient population?

business launch

‘A true breakthrough’: The eye-opening potential of GLP-1 agonists to treat heart, kidney disease in addition to obesity

While GLP-1 drugs were originally developed to treat diabetes, researchers keep finding additional ways these medications can potentially benefit patients.

Dapagliflozin improves symptoms in some, but not all, heart failure patients

The popular SGLT2 inhibitor, sold under the brand name Farxiga, is approved by the FDA to treat heart failure, type 2 diabetes and CKD. Recent data on its ability to affect the symptoms of heart failure patients have been inconsistent. 

Displaying 73 - 80 of 645
Design by Adaptive Theme